Search

Your search keyword '"de Las Heras B"' showing total 260 results
Start Over Author "de Las Heras B"
260 results on '"de Las Heras B"'

3. 108P Pathologic nodal positivity in patients with cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy

Author

Martinez Saez, O., primary, Hernando Melia, C., additional, Rey, M., additional, Chic, N., additional, Martinez, M.T.M., additional, Cebrecos, I., additional, Bermejo De Las Heras, B., additional, Bargalló, X., additional, Burgués, O., additional, Ganau, S., additional, Úbeda, B., additional, Mollá, M., additional, Vidal-Siscart, S., additional, Sanfeliu Torres, E., additional, Gonzalez-Farre, B., additional, Vidal, M., additional, Adamo, B., additional, Munoz, M., additional, Prat, A., additional, and Cejalvo Andujar, J.M., additional

Published
2022
Full Text
View/download PDF

4. 95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study

Author

Pascual, T., primary, Bermejo De Las Heras, B., additional, Martinez, N., additional, Oliveira, M., additional, Pernas Simon, S., additional, Lopez Lopez, R., additional, Ruiz Cabrero, I., additional, Alarcon, J.D., additional, Martinez De Dueñas, E., additional, Malon Gimenez, D., additional, Gonzalez Cao, M., additional, Manso Sanchez, L.M., additional, Morales Murillo, S., additional, Lopez de Ceballos, H., additional, Cortés, J., additional, Llombart Cussac, A., additional, and Prat, A., additional

Published
2022
Full Text
View/download PDF

5. 14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO

Author

Teng, N., primary, Dalby, M.J., additional, Kiu, R., additional, Robinson, T., additional, Gion Cortes, M., additional, Bermejo De Las Heras, B., additional, Perez Garcia, J.M., additional, Calvo-Martinez, L., additional, Prat, A., additional, Marquez Vazquez, R., additional, Ruiz Borrego, M., additional, de la Cruz, S., additional, Llombart Cussac, A., additional, Curigliano, G., additional, Schmid, P., additional, Mancino, M., additional, Hall, L., additional, Robinson, S., additional, Cortés, J., additional, and Malfettone, A., additional

Published
2022
Full Text
View/download PDF

6. 93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial

Author

Gebhart, G., primary, Keyaerts, M., additional, Guiot, T., additional, Flamen, P., additional, Ruiz Borrego, M., additional, Stradella, A., additional, Bermejo De Las Heras, B., additional, Escriva de Romani, S., additional, Calvo-Martinez, L., additional, Ribelles Entrena, N., additional, Martinez, N., additional, Albacar Miro, C.R., additional, Colleoni, M.A., additional, Atienza de Frutos, M., additional, Sampayo-Cordero, M., additional, Cortés, J., additional, Perez Garcia, J.M., additional, and Llombart Cussac, A., additional

Published
2022
Full Text
View/download PDF

7. 62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials

Author

Martin Jimenez, M., primary, Rodríguez-Lescure, A., additional, Andres Conejero, R., additional, Servitja Tormo, S., additional, Anton Torres, A., additional, Ruiz Borrego, M., additional, Bermejo De Las Heras, B., additional, Guerrero, A., additional, Ramos Vazquez, M., additional, Santaballa Bertran, A., additional, Munoz, M., additional, Batista, J.N., additional, Lopez-Tarruella Cobo, S., additional, Chacon Lopez-Muniz, J.I., additional, Alvarez Lopez, I., additional, Martinez del Prado, M.P., additional, Miralles, J.J., additional, Polonio, O., additional, Jara Sanchez, C., additional, and Mori de Santiago, M., additional

Published
2022
Full Text
View/download PDF

8. 208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial

Author

Ciruelos, E.M., primary, Ponce, J., additional, Pernas Simon, S., additional, Cortés, J., additional, Cantos, B., additional, Garate, E., additional, Vega Alonso, E., additional, Mele Olive, M., additional, Martinez De Dueñas, E., additional, Montaño Perianez, A., additional, Martinez, N., additional, Perello Martorell, A., additional, Bermejo De Las Heras, B., additional, Arqueros Nunez, C., additional, Fernández, I., additional, De la Haba Rodriguez, J., additional, Oliveira, M., additional, González, X., additional, Villagrasa Gonzalez, P., additional, and Prat, A., additional

Published
2022
Full Text
View/download PDF

9. Methodological advances in the discovery of novel neuroblastoma therapeutics

Author

Segura MF, Soriano A, Roma J, Piskareva O, Jiménez C, Boloix A, Fletcher JI, Haber M, Gray JC, Cerdá-Alberich L, Martínez de Las Heras B, Cañete A, Gallego S, and Moreno L

Subjects
3D in vitro models, Functional genomics, genetically engineered murine models, immunotherapy, liquid biopsy, neuroblastoma, next generation sequencing, patient-derived xenografts, radiogenomics
Abstract

Neuroblastoma is a cancer of the sympathetic nervous system that causes up to 15% of cancer-related deaths among children. Among the ~1,000 newly diagnosed cases per year in Europe, more than half are classified as high-risk, with a 5-year survival rate

Published
2022

10. Outcomes of high-risk breast cancer (BC) patients from El Alamo IV registry and GEICAM adjuvant clinical trials

Author

Martin Jimenez, M., Rodriguez-Lescure, A., Andres Conejero, R., Servitja Tormo, S., Anton Torres, A., Ruiz Borrego, M., Bermejo De Las Heras, B., Guerrero, A., Ramos Vazquez, M., Santaballa Bertran, A., Munoz, M., Batista, J. N., Lopez-Tarruella Cobo, S., Chacon Lopez-Muniz, J. I., Alvarez Lopez, I., Martinez del Prado, M. P., Miralles, J. J., Polonio, O., Jara Sanchez, C., and Mori de Santiago, M.

Published
2022

15. MR Denoising Increases Radiomic Biomarker Precision and Reproducibility in Oncologic Imaging

Author

Fernández Patón M, Cerdá Alberich L, Sangüesa Nebot C, Martínez de Las Heras B, Veiga Canuto D, Canete Nieto, Adela, and Martí-Bonmatí L

Subjects
Denoising, Image processing, Oncologic imaging biomarkers, Radiomics
Abstract

Several noise sources, such as the Johnson-Nyquist noise, affect MR images disturbing the visualization of structures and affecting the subsequent extraction of radiomic data. We evaluate the performance of 5 denoising filters (anisotropic diffusion filter (ADF), curvature flow filter (CFF), Gaussian filter (GF), non-local means filter (NLMF), and unbiased non-local means (UNLMF)), with 33 different settings, in T2-weighted MR images of phantoms (N = 112) and neuroblastoma patients (N = 25). Filters were discarded until the most optimal solutions were obtained according to 3 image quality metrics: peak signal-to-noise ratio (PSNR), edge-strength similarity-based image quality metric (ESSIM), and noise (standard deviation of the signal intensity of a region in the background area). The selected filters were ADFs and UNLMs. From them, 107 radiomics features preservation at 4 progressively added noise levels were studied. The ADF with a conductance of 1 and 2 iterations standardized the radiomic features, improving reproducibility and quality metrics.

Published
2021

17. 129TiP Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR)[+]/HER2[–] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA

Author

Llombart Cussac, A., primary, Pérez-Garcia, J.M., additional, Blanch, S., additional, Tolosa, P., additional, Ruiz Borrego, M., additional, Gion Cortes, M., additional, Fernádez, A., additional, Urruticoechea, A., additional, Galve, E., additional, Cueva Banuelos, J.F., additional, Ponce, J., additional, Alonso, J.L., additional, Capelán, M., additional, Martínez, E., additional, Bermejo De Las Heras, B., additional, Rojas, B., additional, Martos, T., additional, López, A., additional, Gómez-Peralta, F., additional, and Cortés, J., additional

Published
2021
Full Text
View/download PDF

18. 130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype

Author

Ciruelos, E.M., primary, Garcia, A.A., additional, Cortés, J., additional, Pernas Simon, S., additional, Garate, E., additional, Melé, M., additional, Montaño, Á., additional, Martinez-Jañez, N., additional, Oliveira, M., additional, Haba-Rodríguez, J. de la, additional, Vega, E., additional, Martorell, A. Perello, additional, Bermejo De Las Heras, B., additional, Cantos Sanchez De Ibarguen, B., additional, Martínez, E., additional, Navarro, E. Vila, additional, Pascual, T., additional, González-Farré, X., additional, Villagrasa, P., additional, and Prat, A., additional

Published
2021
Full Text
View/download PDF

19. The economic burden of metastatic breast cancer in Spain

Author

de las Heras B, Cajal J, Calvo E, Rodriguez J, Mata J, Anton F, Fernandez I, Rodriguez-Lescure A, Sanchez C, Ruiz-Borrego M, Remak E, Barra M, Rivero M, and Alvarez J

Subjects
stomatognathic system, skin and connective tissue diseases, neoplasms
Abstract

Objectives The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years. Methods An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles. Results The incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2-/ HR+, 520 HER2+/HR+, 324 HER2+/HR-, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2-/HR+, 2.82 years for HER2+/ HR- and shortest mean survival of 1.74 years for triple negative patients. The total costs were (sic)469,92,731 for the overall population, (sic)190,079,787 for the HER2-/ HR+, (sic)151,045,260 for the HER2+/HR+, (sic)80,827,171 for the HER2+/HR- and _47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were (sic)160,642 on average, (sic)120,664 for HER2-/HR+, (sic)290,346 for HER2+/HR+, (sic)249,152 for HER2+/HR- and (sic)94,572 for triple negative patients over 5 years. Conclusions The economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2-/ HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.

Published
2020

20. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting

Author

Sanchez-Rovira P, Hirschberg A, Gil-Gil M, Bermejo-de las Heras B, and Nieto-Magro C

Subjects
hormones, hormone substitutes, and hormone antagonists
Abstract

Lessons Learned The levels of circulating follicle-stimulating hormone, luteinizing hormone, estriol, estradiol, and estrone remained unchanged after a 12-week treatment with 0.005% estriol vaginal gel in postmenopausal women receiving nonsteroidal aromatase inhibitors for hormone receptor-positive early breast cancer. These results support the safety of 0.005% estriol vaginal gel for the treatment of bothering symptoms of vulvovaginal atrophy in breast cancer survivors. The results provide clinicians with confidence in the use of this product in women who do not experience symptom relief with nonhormonal remedies. Background Symptoms of vulvovaginal atrophy associated with treatment with nonsteroidal aromatase inhibitors (NSAIs) negatively impact patients' quality of life and may affect adherence to NSAIs. Vaginal estrogens effectively improve these symptoms, although their safe use in breast cancer survivors remains unclear. Methods Postmenopausal women with hormone receptor-positive early breast cancer receiving NSAI and moderate-to-severe vaginal dryness were randomized to 0.005% estriol vaginal gel or placebo for 12 weeks. Circulating estrogens, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), were analyzed at baseline and at weeks 1, 3, 8, and 12. The primary safety outcome was the variation in serum FSH from baseline to week 12. Results Sixty-one women (mean age, 59 years) enrolled in the study. Small oscillations were observed in FSH and LH, although they were always maintained within the postmenopausal range. No significant differences were found in the variation of FSH and LH between baseline and week 12 from the physiological variation observed before treatment. Women receiving 0.005% estriol vaginal gel had slightly increased estriol levels at weeks 1 and 3, with a subsequent reduction until normalizing at week 12; estradiol and estrone remained the below limit-of-quantitation in almost all samples. Conclusion Ultralow-dose 0.005% estriol vaginal gel did not significantly influence estrogens, FSH, and LH levels in women with breast cancer receiving NSAI. A transient negligible absorption of estriol and a nonsignificant variation of FSH after 12 weeks were observed. These findings provide confidence for the safe use of 0.005% estriol vaginal gel in women with breast cancer with an indication for treatment with vaginal estrogens.

Published
2020

21. 319P Prognosis for patients with oligometastatic breast cancer who achieve NED status after systemic and local therapy

Author

Aguado, E. Olcina, primary, Martinez, M.T.M., additional, Carbonell-Asins, J.A., additional, Montón-Bueno, J., additional, Ortega, B., additional, Poveda, J., additional, Tapia, M., additional, Moragón, S., additional, Melia, C. Hernando, additional, Candia, L., additional, Simon, S., additional, Adam-Artigues, A., additional, Garrido-Cano, I., additional, Pattanayak, B., additional, Tormo, E., additional, Eroles, P., additional, Lluch, A., additional, De Las Heras, B. Bermejo, additional, and Cejalvo, J.M., additional

Published
2020
Full Text
View/download PDF

22. 354TiP Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study

Author

Todo, F. Rojo, primary, Stradella, A., additional, García-Sáenz, J.A., additional, De Las Heras, B. Bermejo, additional, Romero, J.L. Alfonso, additional, Barnadas, A., additional, Peron, Y. Izarzugaza, additional, Alba, E., additional, López-Tarruella, S., additional, Henao-Carrasco, F., additional, Carrasco, E., additional, Caballero, R., additional, and Del Campo, M., additional

Published
2020
Full Text
View/download PDF

23. 180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial

Author

Ciruelos, E.M., primary, Villagrasa, P., additional, Oliveira, M., additional, Pernas Simon, S., additional, Cortés, J., additional, Vazquez, S., additional, Martínez, N., additional, Perelló, A., additional, Bermejo De Las Heras, B., additional, Martínez, E., additional, Garau Llinas, I., additional, Mele Olive, M., additional, Montaño, A., additional, Vega, E., additional, Cantos, B., additional, Echarri, M.J., additional, Pascual, T., additional, Celiz, P., additional, González-Farré, X., additional, and Prat, A., additional

Published
2020
Full Text
View/download PDF

24. 101P Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial

Author

Llombart Cussac, A., primary, Prat, A., additional, Pérez-García, J.M., additional, Mateos, J., additional, Pascual, T., additional, Escrivà-De-Romani, S., additional, Stradella, A., additional, Ruiz-Borrego, M., additional, Bermejo De Las Heras, B., additional, Keyaerts, M., additional, Sampayo-Cordero, M., additional, Malfettone, A., additional, Cortés, R., additional, Galván, P., additional, Cortés, J., additional, and Gebhart, G., additional

Published
2020
Full Text
View/download PDF

25. 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study

Author

Kahan, Z., primary, Gil-Gil, M., additional, Ruiz-Borrego, M., additional, Carrasco, E.M., additional, Ciruelos, E.M., additional, Muñoz, M., additional, Bermejo De Las Heras, B., additional, Margeli Vila, M., additional, Anton, A., additional, Casas, M., additional, Calvo, L., additional, de la Haba, J., additional, Ramos, M., additional, Álvarez-López, I., additional, Gal-Yam, E., additional, Gautier, E., additional, Corsaro, M., additional, Rodrigálvarez, G., additional, Zielinski, C., additional, and Martin Jimenez, M., additional

Published
2020
Full Text
View/download PDF

32. Abstract OT3-02-05: CORALLEEN: A phase 2 clinical trial of chemotherapy or letrozole plus ribociclib as neoadjuvant treatment for postmenopausal patients with luminal B/HER2-negative breast cancer

Author

Gavila, J, primary, Saura, C, additional, Oliveira, M, additional, Ciruelos, E, additional, Gonzalez, X, additional, de la Peña, L, additional, Bermejo de las Heras, B, additional, Muñoz, M, additional, Fernandez, P, additional, Villagrasa, P, additional, Ortega, V, additional, Lopez, R, additional, Celiz, P, additional, Pascual, T, additional, and Prat, A, additional

Published
2019
Full Text
View/download PDF

34. Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers

Author

Quintela-Fandino, M., primary, Manso Sànchez, L.M., additional, Holgado Martín, E., additional, Moreno, M.C., additional, Morales Murillo, S., additional, Bermejo De Las Heras, B., additional, Malon Gimenez, D., additional, Colomer Bosch, R., additional, Gonzalez Cortijo, L., additional, Hornedo, J., additional, Mouron, S., additional, Muñoz, M., additional, Escudero, S., additional, Blanco, R., additional, and Mañes, S., additional

Published
2018
Full Text
View/download PDF

35. Abstract P3-12-01: 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study”

Author

Sánchez-Rovira, P, primary, Hirschberg, AL, additional, Gil-Gil, M, additional, Antolín-Novoa, S, additional, García-Estévez, L, additional, Bermejo de las Heras, B, additional, Presa-Lorite, J, additional, Sánchez-Vigil de la Villa, I, additional, Suárez-Almarza, J, additional, and Nieto-Magro, C, additional

Published
2018
Full Text
View/download PDF

36. AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression

Author

Cejalvo, J.M., primary, Tormo, E., additional, Adam, A., additional, Rojo, F., additional, Pineda, B., additional, Zazo, S., additional, Gonzalez-Alonso, P., additional, Sabbaghi, M., additional, Alonso, E., additional, Rovira, A., additional, Albanell, J., additional, Bermejo De Las Heras, B., additional, Burgues, O., additional, Lluch, A., additional, Perez Fidalgo, J.A., additional, and Eroles, P., additional

Published
2017
Full Text
View/download PDF

37. SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer

Author

Villagrasa Gonzalez, P., primary, Prat, A., additional, Oliveira, M., additional, de la Pena, L., additional, Gonzalez, X., additional, Cortes Castan, J., additional, Rios, J., additional, Vázquez, J., additional, Martínez Jañez, N., additional, Perelló Martorell, A., additional, Garau, I., additional, Martinez de Dueñas, E., additional, Morales, S., additional, Melé, M., additional, Bermejo De Las Heras, B., additional, and Ciruelos, E., additional

Published
2017
Full Text
View/download PDF

38. Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial

Author

Nuciforo, P., primary, Prat, A., additional, Llombart, A., additional, Fasani, R., additional, Paré, L., additional, Pascual, T., additional, Oliveira, M., additional, Martínez Jañez, N., additional, Bermejo De Las Heras, B., additional, Vidal, M., additional, Pernas Simon, S., additional, López, R., additional, Muñoz, M., additional, Garau, I., additional, Manso, L., additional, Alarcon Company, J., additional, Martinez de Dueñas, E., additional, Villagrasa Gonzalez, P., additional, Cortes Castan, J., additional, and Holgado, E., additional

Published
2017
Full Text
View/download PDF

40. Novel Water-Soluble Mucoadhesive Carbosilane Dendrimers for Ocular Administration

Author

Bravo-Osuna, I., primary, Vicario-de-la-Torre, M., additional, Andrés-Guerrero, V., additional, Sánchez-Nieves, J., additional, Guzmán-Navarro, M., additional, de la Mata, F. J., additional, Gómez, R., additional, de las Heras, B., additional, Argüeso, P., additional, Ponchel, G., additional, Herrero-Vanrell, R., additional, and Molina-Martínez, I. T., additional

Published
2016
Full Text
View/download PDF

43. Effects of Anisakis simplex on Nitric Oxide Production in J774 Macrophages

Author

De Las Heras B, Carmen Cuéllar, and M.J. Perteguer

Subjects
Lipopolysaccharides, Microbiology (medical), Lipopolysaccharide, Nitric Oxide Synthase Type II, Cycloheximide, Biology, Nitric Oxide, Cell Line, Nitric oxide, Mice, chemistry.chemical_compound, parasitic diseases, Extracellular, Animals, Viability assay, Nitrite, General Immunology and Microbiology, Macrophages, General Medicine, Molecular biology, Anisakis, Nitric oxide synthase, Infectious Diseases, chemistry, Biochemistry, Cell culture, biology.protein, Nitric Oxide Synthase
Abstract

Since nitric oxide (NO) was recognized as a potent microbicidal agent, its role in host defence against intracellular parasites has been widely demonstrated. Recent evidence suggests a role for NO in combating extracellular and multicellular pathogens. This defence activity has been demonstrated toward the larvae of Schistosoma mansoni, microfilariae of Onchocerca linealis, several stages of Brugia malayi and protoscoleces of Echinococcus multilocularis. Many parasites suppress Th1 lymphocytes and directly inhibit NO production by inducing cytokines, such as IL-4, IL-10 and TGF-beta. In this study, we have investigated the effects of Anisakis simplex, an enhancer of Th2-dominant responses, on NO production. We studied the effect of crude extracts (CE) and excretory-secretory (ES) products on the induction of inducible nitric oxide synthase (iNOS) in bacterial lipopolysaccharide (LPS)-treated J774 macrophages. Stimulation of macrophages by LPS (1 microg/ml) increased nitrite concentrations in the culture medium at 24 h. Co-administration of A. simplex products with LPS, dose-dependently reduced the accumulation of nitrite. Nitrite production is due to induction of iNOS, and both L-NAME (N(G)-nitro-L-arginine methyl ester) (50 microM) and dexamethasone (10 microM) inhibited nitrite accumulation (54.2 and 92.1% inhibition, respectively). The inhibition of nitrite production by A. simplex was 42.1-97.8% in the range 4.75-76 microg/well (CE products) and 37.2-61.5% in the range 5-20 microg/well (ES products). Cell viability assayed by the mitochondrial-dependent reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) verified that the inhibition was not due to general cellular toxicity. However, the effects of A. simplex, were reduced when NOS had been induced by prior exposure to LPS and any possible further induction was blocked by cycloheximide, an inhibitor of protein synthesis.

Published
1998

45. Molecular basis of the anti-inflammatory effects of terpenoids

Author

de las Heras B and Sonsoles Hortelano

Subjects
Transcriptional Activation, medicine.drug_class, Immunology, Anti-Inflammatory Agents, Biology, Pharmacology, Anti-inflammatory, Autoimmune Diseases, Terpene, Labdane, Human health, chemistry.chemical_compound, Immune system, Drug Therapy, Neoplasms, medicine, Hypersensitivity, Immunology and Allergy, Animals, Humans, Immunosuppression Therapy, Drug discovery, Terpenes, Tumor Necrosis Factor-alpha, NF-kappa B, General Medicine, Terpenoid, Biochemistry, chemistry, Molecular targets, Medicine, Traditional, Diterpenes, Signal Transduction
Abstract

Natural products play a significant role in human health in relation to the prevention and treatment of inflammatory conditions. Among them, terpenoids (also referred to as terpenes), are the largest and most widespread class of secondary metabolites. They are found in higher plants, mosses, liverworts, algae and lichens, and also in insects, microbes or marine organisms. Some terpenoids have been used for therapeutic purposes for centuries as antibacterial, anti-inflammatory, antitumoral agents, and in recent decades research activity into the clinical potential of this class of compounds has increased continuously as a source of pharmacologically interesting agents. In the present review, molecular basis of the anti-inflammatory action of diterpenoids is presented with special emphasis on their ability to modulate critical cell signaling pathways involved in the inflammatory response of the body such as nuclear transcription factor-kappaB (NF-kappaB) activation. NF-kappaB plays an important role in the regulation of immune and inflammatory responses. Indeed, deregulated NF-kappaB expression is a characteristic phenomenon in several inflammatory diseases and NF-kappaB has become a major target in drug discovery. Hence, this article also introduces our recently elucidated findings about the potential of labdane diterpenoids as anti-inflammatory agents due to their ability to inhibit NF-kappaB. The future development of this class of compounds as anti-inflammatory drugs requires the introduction of novel molecular targets of therapeutic relevance in addition to biotechnological approaches for the production of these molecules.

Published
2009

47. 321TiP - SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer

Author

Villagrasa Gonzalez, P., Prat, A., Oliveira, M., de la Pena, L., Gonzalez, X., Cortes Castan, J., Rios, J., Vázquez, J., Martínez Jañez, N., Perelló Martorell, A., Garau, I., Martinez de Dueñas, E., Morales, S., Melé, M., Bermejo De Las Heras, B., and Ciruelos, E.

Published
2017
Full Text
View/download PDF

48. 155PD - Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial

Author

Nuciforo, P., Prat, A., Llombart, A., Fasani, R., Paré, L., Pascual, T., Oliveira, M., Martínez Jañez, N., Bermejo De Las Heras, B., Vidal, M., Pernas Simon, S., López, R., Muñoz, M., Garau, I., Manso, L., Alarcon Company, J., Martinez de Dueñas, E., Villagrasa Gonzalez, P., Cortes Castan, J., and Holgado, E.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results